1.GSK
GSK.L (LSE)
GSK is a top-rated defensive pharmaceutical stock, recognized by AJ Bell analysts for its resilience during economic downturns and strong demand in the healthcare sector. With a solid 1-year return of 43.43% and a dividend yield of 2.77%, it appeals to investors seeking reliable income and growth.
Pros:
- Defensive stock with robust healthcare demand
- Strong performance with 43% increase in the past year
Cons:
- Market volatility risk
- Dependence on healthcare sector performance
2.Shell
SHELL.AS (AMS)
Shell stands out as a robust energy giant, offering a strong dividend yield of 3.5% and showcasing a diversified business model, making it an attractive option for investors seeking reliable income during uncertain times. Despite its shares rising over 12% over the past year and nearing multi-year highs, valuations remain reasonable compared to historical standards in the energy sector. With an A- rating from analysts, Shell continues to be a top-rated choice for income-focused investors.
Pros:
- Strong dividends and free cash flow
- Diversified business model
Cons:
- Uncertainty around long-term oil demand
- Recent weaker-than-expected profits
3.BAE Systems
BSP.DE (XETRA)
BAE Systems stands out as a reliable defense contractor, demonstrating strong earnings momentum amidst ongoing geopolitical tensions. Currently, analysts rate the stock a solid B+, with a 12-month price target averaging around 2,200.25, suggesting potential growth opportunities for investors seeking stability in uncertain times. The company’s recent profit increase, driven by a heightened threat environment, further underscores its robust growth strategy.
Pros:
- Earnings momentum amid geopolitical uncertainty
- Strong growth plans outlined
Cons:
- High P/E ratio compared to historical averages
- Weakening order trends
4.Tesco
TSCO.L (LSE)
Tesco stands out as the UK's largest supermarket, demonstrating impressive sales resilience and profit growth amid fierce competition. With a solid dividend yield of 3.20%, its strong performance is reflected in a 24.89% return over the past year and a remarkable 112.85% over five years. Recommended by top analysts at JP Morgan and Deutsche Bank for its recession-resistant qualities, it’s an attractive option for investors looking for stability in uncertain times.
Pros:
- Sales resilience despite competition
- Profit upgrades recommended by analysts
Cons:
- Valuation towards the top end of peer group
- Potential limited near-term upside
Final Words
As you consider your investment options during this uncertain economic climate, GSK stands out as a resilient choice in the healthcare sector. Take time to compare it with other stocks and conduct your own research to ensure your portfolio is recession-proof.
Frequently Asked Questions
GSK is considered a top pick for recession-proof stocks due to its defensive position in the pharmaceutical sector, which experiences robust healthcare demand even during economic downturns. Analysts from AJ Bell have highlighted it as a strong option in the FTSE 100.
As of early March 2026, GSK has demonstrated solid performance with a 3-month return of 15.77% and a 1-year return of 43.43%. This consistent performance reflects its resilience in the market.
GSK has a dividend yield of approximately 2.77% and pays dividends quarterly. The next dividend payment is scheduled for April 9, 2026.
Recession-proof stocks often belong to sectors such as healthcare, consumer staples, utilities, and essential services. These sectors tend to maintain stable demand regardless of economic conditions.
Investors can identify recession-proof stocks by looking for companies that provide essential goods and services, have strong balance sheets, and demonstrate consistent performance during economic downturns. Researching historical performance during recessions can also be beneficial.
While GSK is positioned as a defensive stock, risks include regulatory changes, market competition, and potential fluctuations in healthcare demand. Investors should consider these factors alongside their investment strategy.
